Delivery Order SPE2DB24D1201-SPE2DB24FJBPF

Award Date 9/19/24
Potential Completion Date 9/20/24
Potential Value $5.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of XARELTO 20 MG tablets. The contract has a ceiling value of $1,657.74 and a completion date of October 25, 2024. This is a delivery order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, covers the delivery of XARELTO 20 MG TABLET 90S to the Defense Logistics Agency (DLA). The $30,784.46 Firm Fixed Price delivery order has a period of performance ending on July 1, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC enables efficient...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,697.97 firm fixed-price delivery order contract covers the supply of XARELTO 20 MG TABLET 90S, a prescription medication, to support military healthcare programs. The contract has an ultimate completion date of November 26, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,625.63 firm fixed-price delivery order is for XARELTO 20 MG TABLET 90S and has an ultimate completion date of January 22, 2025. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of XARELTO 20 MG TABLET 90S. The contract is a Delivery Order with a Firm Fixed Price of $9,734.53 and a completion date of August 8, 2024. This appears to be part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to supply XARELTO 20 MG TABLET 90S to the Defense Logistics Agency (DLA). The firm-fixed-price delivery order, valued at $2,785.80, is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that has a ceiling value of up to $999,999,999 through December 2025. This IDC enables the DLA to efficiently procure a wide range of essential pharmaceutical and medical...
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,679.46 firm-fixed-price delivery order is for the supply of XARELTO 20 MG TABLET 90S, a cardiovascular medication. The contract has an ultimate completion date of December 9, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
This federal contract award is for the delivery of XARELTO 20 MG TABLET 90S to the Defense Logistics Agency (DLA). The $32,906.13 firm fixed price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on August 27, 2024, with a completion date of August 28, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for...
This is a $11,292.90 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XARELTO 20 mg tablets. The contract has an ultimate completion date of October 9, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a wide range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,276.15 firm fixed-price delivery order is for the supply of XARELTO 20 MG TABLET 90S, a prescription medication. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical valued at $999,999,999, which provides a comprehensive range of...
  • SPE2DB24D1201
    Indefinite Delivery Contract
  • SPE2DB24D1201-SPE2DB24FJBPF
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of XARELTO 20 MG TABLET 90S. The $5,192.68 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025. This IDC enables the DLA to efficiently procure a comprehensive range of medical commodities, including prescription drugs, to support military treatment programs and facilities worldwide. The contract has no set-aside designation and is scheduled for completion by September 20, 2024.

Generated 12/19/24, 9:31 AM